# Atea Pharmaceuticals Inc. (AVIR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.83, market value $468 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Atea Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.3×**. Each dollar of revenue is priced at 1.3×.
- **Price / book: 2.3×**. The shares trade at 2.3× book value; book value is a meaningful part of the valuation.

## Profitability
- **Operating margin: 39.4%**. 39.4% of revenue is left after running the business, an exceptional level.
- **Return on equity: -57.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: 38.4%**. Each dollar of assets produces 38.4% of profit.

## Growth
- **EPS growth (1 yr): 3.0%**. Earnings per share rose 3.0%.

## Financial health
- **Current ratio: 7.82** (quick 7.82). Current assets cover the next year's liabilities 7.82 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Atea Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (3 analysts). 3 analysts cover Atea Pharmaceuticals Inc.; the consensus is buy, with an average price target of $9.42 (+62% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 75.1%** (YTD 63.3%, 3-mo 37.2%). The shares are up 75.1% over twelve months including dividends.
- **From 52-week high: -9.6%** (109.7% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 69**. An RSI of 69 is neutral.
- **Beta (1 yr): 0.59** (volatility 50%). Beta of 0.59 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AVIR · Page: https://foliofundamentals.com/stocks/avir

Not investment advice.